Item 1.
|
Security and Issuer
|
This Amendment No. 1 to Schedule 13D (Amendment No.1) amends and supplements the statement on Schedule 13D originally filed with the
Securities and Exchange Commission on March 22, 2019 (the Original Schedule 13D) by ABIOMED, Inc., a Delaware corporation (ABIOMED), relating to the common stock, par value $0.001 per share (Common
Stock), of ShockWave Medical, Inc., a Delaware corporation (the Issuer). Except as otherwise specified in Amendment No.1, all items in the Original Schedule 13D are unchanged. Unless otherwise indicated, each capitalized
term used but not defined herein shall have the meaning assigned to such term in the Original Schedule 13D. This Amendment constitutes an exit filing of ABIOMED.
Item 5.
|
Interest in Securities of the Issuer
|
(a, b) The percentage of beneficial ownership reported in this Item 5, and on the cover page to this Schedule 13D, is based on a total of 33,782,606 shares of
Common Stock issued and outstanding as of June 19, 2020, as reported in the Issuers prospectus, dated as of June 17, 2020, relating to the issuance and sale of 1,955,000 shares of Common Stock (the Offering). All
of the share numbers reported below, and on the cover page to this Schedule 13D, are as of June 19, 2020, unless otherwise indicated. The cover page to this Schedule 13D is incorporated by reference in its entirety into this Item 5(a, b).
ABIOMED directly holds, and thus has sole voting and dispositive power over, 1,610,843 shares of Common Stock, or approximately, 4.77% of the outstanding
shares of Common Stock.
(c) ABIOMED has not effected any transaction in shares of the Common Stock from March 21, 2019 to July 13, 2020. On
July 14, 2020, ABIOMED sold 68,000 shares of Common Stock.
(e) As a result of the Offering, the Reporting Persons have ceased to be the beneficial
owners of more than five percent of the Companys Common Stock based on the number of shares of Common Stock outstanding as reported by the Company as of June 19, 2020.
Item 7.
|
Material to be Filed as Exhibits
|
|
|
|
Exhibit 1
|
|
Amended and Restated Investor Rights Agreement between the Issuer and the investors listed on Exhibit A thereto (incorporated by reference to Exhibit 4.1 to the Issuers Registration Statement on Form S-1 (File No. 333-229590) initially filed by the Issuer with the SEC on February 8, 2019).
|
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this
statement is true, complete and correct.
|
|
|
DATE:
|
|
July 15, 2020
|
|
ABIOMED, INC.
|
By:
|
|
/s/ Marc A. Began
|
|
|
Marc Began
Vice President, General Counsel
and Secretary
|